Logo

Amgen

Amgen Spotlights Investigational Precision Oncology Candidates as Q1 Revenue Jumps 9 Percent
Premium

The firm is expecting Phase III readouts this year for its FGFR2b drug bemarituzumab and is advancing a second KRAS inhibitor to the clinic.

EntroGen Colorectal Cancer RAS Mutation Detection Test Nabs CMS Coverage

The real-time PCR-based companion diagnostic test identifies patients eligible for treatment with Amgen's Vectibix (panitumumab).

UK's NICE Approves Blincyto as Frontline Consolidation Treatment for Certain Leukemia Patients

Blincyto plus chemo was approved for adult patients with Ph-negative, CD19-positive, and MRD-negative B-cell precursor acute lymphoblastic leukemia.

Amgen Reports More Than $2B in Oncology Revenues in Q4

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

EC Approves Amgen's Blincyto as Consolidation Treatment for Certain Newly Diagnosed Leukemia Cases

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

Jan 17, 2025

Amgen's Lumakras, Vectibix Net FDA Approval in KRAS G12C-Mutant Colorectal Cancer

Oct 31, 2024

Amgen Sees Strong Growth for Precision Oncology Drugs in Q3

Sep 18, 2024

Amgen's Lumakras Combo Scores High Response Rate in First-Line KRAS-Mutant Colorectal Cancer
Premium

Aug 7, 2024

Amgen Invests in Late-Stage Pipeline as Q2 Revenues Grow 20 Percent
Premium

Jul 9, 2024

Ideaya Biosciences Talks Registration-Directed Trials for IDE397 After Early Interim Data
Premium

Jun 17, 2024

FDA Approves Amgen's Blincyto as Consolidation Treatment in Certain Pediatric, Adult ALL Patients

May 3, 2024

Amgen's Lumakras Reports Double-Digit Sales Growth in Q1

Apr 11, 2024

FDA Asks Experts if MRD Can Be an Accelerated Approval Endpoint in Multiple Myeloma Trials
Premium

Apr 4, 2024

Drugmakers Clamor to Prove 'Lp(a) Hypothesis' in Cardiovascular Disease
Premium

Mar 26, 2024

Volastra Therapeutics Inks Two New Deals to ID Biomarkers for KIF18A Inhibitor Patient Selection

Mar 13, 2024

FDA Wants Expert Input on Benefits, Risks of CAR T Therapy in Earlier-Line Multiple Myeloma

Feb 7, 2024

Amgen Reports Sales Growth Across Precision Oncology Products in Q4
Premium

Dec 27, 2023

FDA Denies Full Approval of Amgen's Lumakras, Requests Additional Confirmatory Study

Dec 4, 2023

Ideaya Biosciences, Gilead Sciences to Study IDE397-Trodelvy Combo in MTAP-Null Bladder Cancer

Dec 1, 2023

Intermountain Health Spinout Culmination Bio on Growth Trajectory After $10M Investment
Premium

Nov 8, 2023

Amgen Testing Clinical Outcomes of Promising Lp(a)-Targeting Cardiovascular Drug in Phase III Trial
Premium

Nov 6, 2023

UK's MHRA Conditionally Approves Mirati's Krazati for Advanced KRAS-Mutated NSCLC

Oct 25, 2023

Amgen Eager for Regulatory Discussions After Lumakras-Vectibix CodeBreaK 300 Data in Colon Cancer
Premium

Oct 9, 2023

Bristol Myers Squibb Scooping Up Mirati Therapeutics, KRAS Inhibitor in $4.8B Deal

Oct 6, 2023

FDA Advisors Find Lumakras Data Unreliable But Still See Potential Benefit in KRAS-Mutant NSCLC
Premium